184 related articles for article (PubMed ID: 25553462)
1. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Hao Z; Huang S
Front Biosci (Landmark Ed); 2015 Jan; 20(3):474-90. PubMed ID: 25553462
[TBL] [Abstract][Full Text] [Related]
2. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.
Hershko DD
Cancer; 2008 Apr; 112(7):1415-24. PubMed ID: 18260093
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
6. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
7. Skp2 Inhibitors: Novel Anticancer Strategies.
Lee Y; Lim HS
Curr Med Chem; 2016; 23(22):2363-79. PubMed ID: 27160538
[TBL] [Abstract][Full Text] [Related]
8. Skp2 in the ubiquitin-proteasome system: A comprehensive review.
Asmamaw MD; Liu Y; Zheng YC; Shi XJ; Liu HM
Med Res Rev; 2020 Sep; 40(5):1920-1949. PubMed ID: 32391596
[TBL] [Abstract][Full Text] [Related]
9. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Wang G; Chan CH; Gao Y; Lin HK
Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
[TBL] [Abstract][Full Text] [Related]
10. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
11. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
13. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
[TBL] [Abstract][Full Text] [Related]
16. TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
Pavlides SC; Lecanda J; Daubriac J; Pandya UM; Gama P; Blank S; Mittal K; Shukla P; Gold LI
Cell Cycle; 2016; 15(7):931-47. PubMed ID: 26963853
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated expression of SKP2 and its role in hematological malignancies.
Kulinski M; Achkar IW; Haris M; Dermime S; Mohammad RM; Uddin S
Leuk Lymphoma; 2018 May; 59(5):1051-1063. PubMed ID: 28797197
[TBL] [Abstract][Full Text] [Related]
18. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
[TBL] [Abstract][Full Text] [Related]
19. The Skp2 Pathway: A Critical Target for Cancer Therapy.
Cai Z; Moten A; Peng D; Hsu CC; Pan BS; Manne R; Li HY; Lin HK
Semin Cancer Biol; 2020 Dec; 67(Pt 2):16-33. PubMed ID: 32014608
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.
Feng Z; Yin J; Zhang Z; Chen Z; Huang L; Tang N; Wang K
Oncogene; 2024 Apr; 43(15):1149-1159. PubMed ID: 38396292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]